| Not Yet Recruiting | TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma Esophagogastric Adenocarcinoma | Phase 2 | 2026-07-01 |
| Not Yet Recruiting | Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy | Phase 2 | 2026-06-01 |
| Recruiting | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroeso Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer | Phase 2 | 2026-01-16 |
| Recruiting | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis) | — | 2025-12-23 |
| Recruiting | NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy Hepatocellular Carcinoma (HCC) | — | 2025-12-17 |
| Recruiting | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab fo Penile Squamous Cell Carcinoma (PSCC) | Phase 2 | 2025-12-16 |
| Recruiting | Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities Colorectal Cancer | Phase 2 | 2025-12-16 |
| Recruiting | A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for R Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 1 | 2025-12-12 |
| Recruiting | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangioca Cholangiocarcinoma, IDH Mutation | Phase 2 | 2025-11-18 |
| Recruiting | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Profic Metastatic Colorectal Cancer | Phase 2 | 2025-10-27 |
| Recruiting | Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC Basal Cell Carcinoma (BCC), First Line Treatment | Phase 2 | 2025-08-07 |
| Recruiting | Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for Esophagogastric Adenocarcinoma | Phase 1 / Phase 2 | 2025-03-25 |
| Active Not Recruiting | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophagea Metastatic Gastro-esophageal Adenocarcinoma | Phase 2 | 2025-03-03 |
| Recruiting | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA | Phase 2 | 2024-08-23 |
| Completed | Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinom Esophagogastric Adenocarcinoma | Phase 1 / Phase 2 | 2024-04-17 |
| Active Not Recruiting | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliar Biliary Tract Cancer, HER2 Gene Mutation, HER2 | Phase 2 | 2024-04-17 |
| Recruiting | Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer Breast Cancer | Phase 2 | 2024-01-17 |
| Terminated | Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma P Soft Tissue Sarcoma | — | 2023-10-31 |
| Recruiting | Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therap Esophagus Adenocarcinoma | Phase 2 | 2023-08-28 |
| Active Not Recruiting | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing Non-small Cell Lung Cancer | Phase 2 | 2023-05-26 |
| Active Not Recruiting | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggress Lymphoma, Large B-Cell, Diffuse | Phase 2 | 2023-03-20 |
| Active Not Recruiting | Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophago Esophagogastric Adenocarcinoma | Phase 2 | 2023-02-13 |
| Terminated | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements Intrahepatic Cholangiocarcinoma, FGFR2 Gene Mutation, FGFR2 Gene Rearrangement | Phase 2 | 2022-11-11 |
| Completed | Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Esophagogastric Adenocarcinoma | Phase 2 | 2022-09-15 |
| Completed | New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platfor Biliary Tract Cancer, Neoadjuvant, Adjuvant and 1st Line | — | 2022-07-12 |
| Completed | Fedratinib in Combination With Nivolumab Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | 2022-06-14 |
| Completed | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma | Phase 2 | 2022-05-23 |
| Completed | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ Hepatocellular Carcinoma | Phase 2 | 2022-05-11 |
| Active Not Recruiting | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements Intrahepatic Cholangiocarcinoma | Phase 2 | 2022-04-20 |
| Completed | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarco Leiomyosarcoma | Phase 2 | 2021-11-15 |
| Recruiting | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-st Hepatocellular Carcinoma | Phase 3 | 2021-07-06 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC Hepatocellular Carcinoma Non-resectable, HCC | Phase 2 | 2020-12-15 |
| Completed | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | Phase 2 | 2020-12-08 |
| Terminated | The PLATON Network Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer | — | 2020-10-28 |
| Completed | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer | N/A | 2020-10-28 |
| Completed | Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophagea Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction | N/A | 2020-10-15 |
| Completed | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | 2020-10-12 |
| Completed | Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease Small Cell Lung Cancer Extensive Stage, Thoracic Radiotherapy | Phase 2 | 2020-07-28 |
| Completed | Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy NSCLC, Stage III | Phase 2 | 2020-05-20 |
| Active Not Recruiting | Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping NSCLC | Phase 2 | 2020-03-30 |
| Terminated | Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Solid Tumor | — | 2020-01-30 |
| Active Not Recruiting | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) Intrahepatic Cholangiocarcinoma | Phase 2 | 2019-11-01 |
| Completed | PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer Pancreatic Adenocarcinoma | — | 2019-10-24 |
| Completed | Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma Advanced Hepatocellular Carcinoma | Phase 2 | 2019-06-12 |
| Completed | IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC Hepatocellular Carcinoma (HCC) | Phase 2 | 2019-05-09 |
| Completed | Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Th Squamous Cell Carcinoma of the Esophagus | Phase 2 | 2019-03-08 |
| Terminated | CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check P Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes) | — | 2019-03-08 |
| Completed | Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery Pleural Mesothelioma Malignant | Phase 2 | 2019-02-04 |
| Completed | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Colorectal Cancer | Phase 3 | 2019-01-24 |
| Recruiting | GISAR German Interdisciplinary Sarcoma Registry Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone | — | 2018-11-29 |
| Terminated | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients Advanced Soft Tissue Sarcoma | Phase 2 | 2018-11-12 |
| Completed | Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untrea Adenocarcinoma of the Stomach, GastroEsophageal Cancer | Phase 2 | 2018-11-07 |
| Completed | Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorect Colorectal Cancer | Phase 2 | 2018-09-28 |
| Active Not Recruiting | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2018-09-14 |
| Active Not Recruiting | Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Gallbladder Carcinoma | — | 2017-10-11 |
| Active Not Recruiting | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors Solid Tumors, Peritoneal Carcinomatosis, NSCLC Adenocarcinoma | Phase 1 | 2017-08-15 |
| Active Not Recruiting | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Ca Advanced Gastric or EGJ Cancer | Phase 2 / Phase 3 | 2017-05-10 |
| Completed | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Stomach Cancer, Gastroesophageal Junction Cancer | Phase 2 / Phase 3 | 2016-06-01 |
| Completed | FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Stomach Cancer, Gastroesophageal Junction Cancer | Phase 2 / Phase 3 | 2016-06-01 |
| Completed | Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CR Metastatic Colorectal Cancer | Phase 2 | 2015-03-01 |
| Completed | Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, In Metastatic Pancreatic Cancer | — | 2014-12-01 |
| Completed | Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer Gastric Cancer | Phase 2 | 2013-09-01 |